## 

### Novartis Patient Support<sup>™</sup>

## FABHALTA® (iptacopan) START FORM

\* = REQUIRED FIELDS

#### Please fill out all fields on this form to enroll in Novartis Patient Support.

**Vaccination Support**<sup>†</sup> **Only:** Check this box and complete all required fields below if you would like to enroll in vaccination support **only** for your patient (and no other services).

#### **1. Patient Information**

First Name*	Last Name*		Email			
Date of Birth (MM/DD/YYY)	Sex for Clinical Use*: [	] Male [_] Female	Phone Number* <sup>‡</sup> —We'll keep you updated through non-marketing calls and texts OK to Leave Voicemail: Yes No			
Address (No PO Box)*						
City	State	ZIP	Preferred Language: English Spanish Other:			
I give permission to disclose my	personal health information to the	following Caregive	er (optional):			
Caregiver Name		Relationship	to Patient			
Caregiver Phone Number-We	ll keep you updated through non-marketing c	calls and texts.				
	and Additional Enrollment Co Patient Authorization on page 3.	onsents				
$\rightarrow$ X	allont hathonization on page 6.		/ /			
Patient/Authorized Re	presentative Signature*		Date (MM/DD/YYYY)*			
CO-PAY PLUS <sup>§</sup>		SUPPORT FROM NOVAR	TIS PATIENT SUPPORT			
I have read and agree to the Co-Pa on page 3.	y Plus Terms and Conditions You can als I agree with	so get continued one-on-o ee to receive marketing cal an autodialer or prerecord	one support from your dedicated Novartis Patient Support Team by checking the box below. Ils and texts from and on behalf of Novartis and its affiliates, including calls and texts made ed voice, at the phone number(s) I provide. I understand that my consent is not required and ny goods or services from Novartis.			
3. Insurance Information						
To prevent delays, please inclue prescription insurance.	de copies (front and back) of the pa	tient's prescription	insurance card(s). Include primary and secondary			
Check all that apply*: Prin	nary 🗌 Secondary 🗌 Prescri	ption 🗌 Patient I	sUninsured			
4. Prescriber Information						
First Name*	Last Name*	Practic	ractice Name			
Address		Practic	e Phone Number			
City	State ZIP*	Office	Contact Name Office Contact Phone			
Prescriber NPI Number*		Office	Fax*			
Tax ID Number	State License N	umber Office	Email			
Page1of3	Send Fax 1-877-44FABHA (1-877-443 blete entire form and fax to Novar	3-2242) 🕛 1	<b>Questions? Call</b> I <b>-833-99FABHA</b> (1-833-993-2242) t at 1-877-44FABHA (1-877-443-2242).			

An incomplete Start Form may delay the start of treatment.

| 1

## 

Novartis Patient Supp	ort	<b>FABHALTA® (iptacopan) START FORM</b>								
5. Vaccination Info	ion Information Patient Name* Date of Birth (MM/DD/YYYY)*									
<b>by telephone at 1-866</b> <b>Please select one of t</b> Vaccinate patients aga	6-201-3101 or or he options belo inst encapsulate	k Evaluation and Mitigation Stra nline at www.FABHALTA-REMS. wand sign the prescriber attest ad bacteria, including <i>Streptococcu</i> ling to current ACIP recommendat	.com. tation*: us pneumoniae, N	- eisseria meningitidis (serogro	oups A, C, W,					
I have reviewed the antibiotic prophylax as soon as possible <b>OR</b> <b>HOLD SHIPMENT</b> I have reviewed the	FABHALTA vac kis will be prescri  <b>CONTACT O</b> FABHALTA vac	NO PRESCRIBER HOLD cination requirements and my patie bed and will be continued until vac <b>PFFICE PRIOR TO DISPENSE</b> cination requirements and my patie o my office as necessary.	cinations have bee	en completed. FABHALTA is a	authorized to	o be dispensed	I			
Current ACIP recommend	dations available a x below if your pati	antibiotic prophylaxis information at: https://www.cdc.gov/vaccines/hcp ient will need vaccination support to he	/acip-recs/index.ht	ml			ıp with you			
My patient requires v	accination suppor	t from Novartis Patient Support.								
Antibiotic prophylax		-	(MM/DD/)	,						
		appropriate vaccine type, brand admir		ninistration date (using the MM/L	D/YYYYY form	nat) of the most rec	cent dose.			
Menacwi	1st Dose Date:   //   2nd Dose Date:   //     Menveo   Menactra   MenQuadfi   Menveo   MenQuadfi									
MenB	1st Dose Date: _	// ] Trumenba	2nd Dose Date: _	7		i <b>te:</b> / ble to Trumenba	_/			
Pneumococcal	1st Dose Date: // 2nd Dose Date: //   PCV13 PCV20 PPSV23 PCV15 PCV20									
НІВ	1st Dose Date:   //   If applicable     ActHIB   Hiberix   If applicable									
6. Prescription Inf										
Preferred Specialty P	_	Onco360 Biologics	_							
Primary Diagnosis Coo		Paroxysmal nocturnal hemoglobi	nuria 📋 Other:							
Pharmacy Prescriptic	и <b>п:</b>			Quantity (60 or 180 capsules)						
Product Information			•			Refills				
FABHALTA 200 mg c	apsule	200 mg orally twice daily		capsules	11 re	efills, or	refills			
I certify the above therap the patient named on thi Patient Assistance Foun for credit, or submitted for that Novartis and NPAF electronically, by facsimi <b>authorized me under H</b> enrollment, Novartis m	ize these instruction by is medically necess of orm. I certify that idation, Inc., and its or reimbursement i may revise, change ile, or by mail to the <b>IIPAA and state la</b>	ons by signing at the end of this section essary and this information is accurate t any medication received from Novartis service providers ("NPAF"), will be used n any form. I acknowledge that NPAF is e, or terminate their respective programs appropriate dispensing pharmacies. I h w to disclose their information to Nov titent by phone, text, and email.	to the best of my know Pharmaceuticals Co donly for the patient r exclusively for purpors s at any time. I author wave discussed the I	prporation, its affiliates and service named on this form and will not be uses of patient care and not for rer ize Novartis and NPAF to forward <b>Novartis Patient Support Progr</b>	e providers ("N offered for sa nuneration of , as my agent, <b>am with my p</b>	Novartis") or the Novartis") or the Novartis") or barter, r any sort. I understa these prescription: patient, who has	vartis returned and s			
$\rightarrow x$						/	/			
Prescriber Sigr ATTN: Please follow		e as Written) (Substitution scribing guidelines for electronic p		Prescriber Name (Print l oplicable).	Name)*	Date (MM/DD/	ΥΥΥΥ)*			
Page 2 of 3	1-8	nd Fax 77-44FABHA (1-877-443-2242 ntire form and fax to Novartis Pat An incomplete Start Form	2) <b>U 1-83</b> tient Support at 1-	start of treatment.		FABHALT/				

# 

## Novartis Patient Support

### **Patient Authorization**

I authorize my healthcare providers, pharmacies and health insurers, and their service providers ("Providers") to disclose information relating to my insurance benefits, medical condition, treatment, and prescription details ("Personal Information") to Novartis Pharmaceuticals Corporation, its affiliates and service providers ("Novartis") and the Novartis Patient Assistance Foundation, Inc., and its service providers ("NPAF") so they can provide the following support services (the "Services"):

- Help coordinate insurance coverage for, access to, and receipt of my medication.
- Communicate with me about possible financial assistance, including Novartis copay or NPAF programs, and, if I am enrolled, administer my participation in those programs.
- Communicate with me about my medication and treatment, including reminders, health and lifestyle tips, and product and other related information. Communications may be customized based on Personal Information obtained from my Providers.
- · Conduct quality assurance and other internal business activities and ask for feedback related to the Services or my treatment.

In delivering the Services, Novartis and NPAF may share my Personal Information with each other, with my Providers, or with government agencies or other financial assistance programs that might help me pay for my medication. They may combine information collected from me with information collected from other sources and use that information to administer the Services. My pharmacies or other healthcare providers may receive payment from Novartis or NPAF for providing certain Services, such as medication or refill reminders, based on my enrollment or participation. Once I authorize disclosure of my Personal Information, it may no longer be protected by federal health privacy law and applicable state laws.

I understand I do not have to sign this Authorization to get my medication or insurance coverage, that I have a right to a copy, and can cancel this Authorization at any time by calling 1-833-99FABHA (1-833-993-2242) or by writing to:

Novartis Patient Support Novartis Pharmaceuticals Corporation One Health Plaza East Hanover, NJ 07936-1080

This Authorization will expire 5 years after I sign it, or earlier if required by state law, unless I cancel it sooner. If I cancel it, I may no longer qualify for Services from Novartis or NPAF, but it will not impact my Provider's treatment or my insurance benefits. I also understand that if a Provider is disclosing my Personal Information to Novartis or NPAF on an authorized, ongoing basis, my cancellation will be effective with respect to that Provider as soon as they receive notice of my cancellation. Cancellation will not affect prior uses or disclosures.

### **Novartis Patient Support Terms and Conditions**

\*Vaccination Support: Limitations apply. Please contact Novartis Patient Support at 1-833-99FABHA (1-833-993-2242) for more information.

<sup>8</sup>**Co-Pay Plus:** Limitations apply. Patients with commercial insurance coverage for FABHALTA may receive up to \$20,000 in annual co-pay benefits for the cost of FABHALTA and up to \$1,000 for qualifying vaccination costs (excluding administrative fees). Patient is responsible for any costs once limit is reached in a calendar year. Program not valid (i) under Medicare, Medicaid, TRICARE, VA, DoD, or any other federal or state health care program, (ii) where patient is not using insurance coverage at all, (iii) where the patient's insurance plan reimburses for the entire cost of the drug, or (iv) where product is not covered by patient's insurance. The value of this program is exclusively for the benefit of patients and is intended to be credited towards patient out-of-pocket obligations and maximums, including applicable co-payments, coinsurance, and deductibles. Patient may not seek reimbursement for the value received from this program from other parties, including any health insurance program. Valid only in the United States, Puerto Rico and select territories. Void where prohibited by law. Additional restrictions may apply. This Program is not health insurance. Program may not be combined with any third-party rebate, coupon, or offer. Proof of purchase may be required. Novartis reserves the right to rescind, revoke, or amend the Program and discontinue support at any time without notice.

**Bridge Program:** Limitations apply. Patients with commercial insurance, a valid prescription for FABHALTA, and a denial of insurance coverage based on a prior authorization requirement may receive a monthly dose for up to 12 months or until insurance coverage approval, whichever occurs first. Not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, VA, DoD or any other federal or state program, or where prohibited by law. A prior authorization and/or appeal of coverage denial must be submitted within 90 days to remain in the program. No purchase necessary. Program is not health insurance, nor is participation a guarantee of insurance coverage. Additional restrictions may apply. Novartis reserves the right to rescind, revoke or amend this Program without notice.


\*Novartis Patient Support may call and text you at the numbers provided for non-marketing purposes (e.g., to help you access and start on FABHALTA). Calls may be autodialed or prerecorded. Message and data rates may apply. You may change your communication preferences at any time by calling 1-833-99FABHA (1-833-993-2242).

Please see full Prescribing Information, including Boxed WARNING and Medication Guide.

Please see the Novartis Pharmaceuticals Corporation Privacy Policy at http://www.novartis.com/us-en/privacy.

FABHALTA and FABHALTA logo are registered trademarks of Novartis AG.

# **U** NOVARTIS





3